BRPI0911384A8 - Canabinóides em combinação com agentes quimioterápêuticos não canabinóides (por exemplo, agentes de alquilação ou serm) - Google Patents

Canabinóides em combinação com agentes quimioterápêuticos não canabinóides (por exemplo, agentes de alquilação ou serm)

Info

Publication number
BRPI0911384A8
BRPI0911384A8 BRPI0911384A BRPI0911384A BRPI0911384A8 BR PI0911384 A8 BRPI0911384 A8 BR PI0911384A8 BR PI0911384 A BRPI0911384 A BR PI0911384A BR PI0911384 A BRPI0911384 A BR PI0911384A BR PI0911384 A8 BRPI0911384 A8 BR PI0911384A8
Authority
BR
Brazil
Prior art keywords
agents
cannabinoids
combination
serm
cannabinoid chemotherapeutic
Prior art date
Application number
BRPI0911384A
Other languages
English (en)
Inventor
Velasco Diez Guillermo
Guzman Pastor Manuel
Lorente Mar
Torres Sofia
Original Assignee
Gw Pharma Ltd
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gw Pharma Ltd, Otsuka Pharma Co Ltd filed Critical Gw Pharma Ltd
Publication of BRPI0911384A2 publication Critical patent/BRPI0911384A2/pt
Publication of BRPI0911384A8 publication Critical patent/BRPI0911384A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

CANABINÓIDES EM COMBINAÇÃO COM AGENTES QUIMIOTERAPÊUTICOS NÃO CANABINÓIDES (POR EXEMPLO, AGENTES DE ALQUILAÇÃO OU SERM) A invenção refere-se ao uso de um ou mais canabinóides, particularmente THC e/ou CBD em combinação com um agente quimioterpêutico não canabinóide na fabricação de um medicamento para uso no tratamento de câncer, mais particularmente um glioma, mais particularmente ainda uma glioblastoma multiforme (GBM). O agente quimioterapêutico de não canabinóide pode ser um modulador de receptor de estrogênio seletivo ou um agente de alquilação.
BRPI0911384A 2008-06-04 2009-06-04 Canabinóides em combinação com agentes quimioterápêuticos não canabinóides (por exemplo, agentes de alquilação ou serm) BRPI0911384A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0810203.0A GB2460672B (en) 2008-06-04 2008-06-04 Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents
PCT/GB2009/050620 WO2009147438A1 (en) 2008-06-04 2009-06-04 Cannabinoids in combination with non -cannabinoid chemotherapeutic agents (e.g. serm or alkylating agents)

Publications (2)

Publication Number Publication Date
BRPI0911384A2 BRPI0911384A2 (pt) 2015-12-29
BRPI0911384A8 true BRPI0911384A8 (pt) 2018-04-03

Family

ID=39638156

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911384A BRPI0911384A8 (pt) 2008-06-04 2009-06-04 Canabinóides em combinação com agentes quimioterápêuticos não canabinóides (por exemplo, agentes de alquilação ou serm)

Country Status (24)

Country Link
US (3) US20110086113A1 (pt)
EP (2) EP3213748B1 (pt)
JP (2) JP5674649B2 (pt)
KR (1) KR20110053944A (pt)
CN (1) CN102083426B (pt)
AR (1) AR072002A1 (pt)
AU (1) AU2009254935B2 (pt)
BR (1) BRPI0911384A8 (pt)
CA (1) CA2726257C (pt)
CO (1) CO6341551A2 (pt)
DK (1) DK2320881T3 (pt)
ES (2) ES2653200T3 (pt)
GB (2) GB2475183B (pt)
IL (1) IL209739A0 (pt)
MX (1) MX2010013036A (pt)
MY (1) MY156264A (pt)
NZ (1) NZ589373A (pt)
PT (1) PT2320881T (pt)
RU (1) RU2543034C2 (pt)
SG (1) SG191643A1 (pt)
TW (1) TWI469777B (pt)
UA (1) UA104589C2 (pt)
WO (1) WO2009147438A1 (pt)
ZA (1) ZA201008558B (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2554592B (en) * 2010-03-12 2018-07-11 Gw Pharma Ltd A glioma treatment Comprising Temozolomide with a mixture of THA and CBD ar a ration of 1:1
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
GB201217285D0 (en) * 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
EP2719375A1 (en) * 2012-10-10 2014-04-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
ES3055185T3 (en) 2014-03-28 2026-02-10 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
CA2974292C (en) 2015-01-31 2024-04-16 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
US20170189373A1 (en) * 2015-05-15 2017-07-06 Andrew Hospodor Terpene Control in Scaleable Cannabinoid Medicinal Formulations
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
EP3368024B1 (en) * 2015-10-27 2023-09-20 Akos Biosciences, Inc. Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
EP3380096A4 (en) 2015-11-24 2019-10-23 Constance Therapeutics, Inc. CANNABIS OIL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
CA3079537A1 (en) * 2017-09-02 2019-03-07 Scientific Holdings, Llc Tetrahydrocannabinol modulators
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2020160452A1 (en) * 2019-02-01 2020-08-06 Tess Ventures, Inc. Combining serms, sarms, and cannabinoids for improving safety and efficacy of endocrine therapies
GB201903546D0 (en) * 2019-03-15 2019-05-01 Ldn Pharma Ltd Cancer treatment
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
WO2021028646A1 (en) * 2019-08-09 2021-02-18 Jay Pharma Inc. Administration regimes of cannabinoids in combination with chemotherapeutics against cancer
US12453711B2 (en) 2019-08-19 2025-10-28 Diverse Biotech, Inc. Platinum complex anti-neoplastic agents comprising a cannabinoid ligand
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
AU2020358869A1 (en) 2019-10-03 2022-04-14 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
EP4041209A4 (en) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
GB202013765D0 (en) 2020-09-02 2020-10-14 Gw Res Ltd Method of preparing cannabinoids
GB2602019A (en) 2020-12-15 2022-06-22 Gw Res Ltd Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
CA3235074A1 (en) 2021-10-26 2023-05-04 Alexandra M CAPANO Methods of treating ovarian cancer with hemp extract
IL312245A (en) 2021-10-26 2024-06-01 Ecofibre Usa Inc Methods of treating endometriosis and other non-cancerous gynecological disorders with hemp extract
EP4422769A2 (en) 2021-10-26 2024-09-04 Ecofibre USA Inc. Systems and methods for producing hemp extracts and compositions
AU2022376836A1 (en) 2021-10-26 2024-05-23 Dove Innovation Pty Limited Methods of treating head and neck cancers with hemp extract
AU2023321655A1 (en) 2022-08-12 2025-02-13 Jazz Pharmaceuticals Research Uk Limited Oral solid dosage forms comprising cannabinoids
IL320517A (en) 2022-10-26 2025-06-01 Ecofibre Usa Inc Methods for treating estrogen-sensitive diseases with cannabis extract
EP4608426A1 (en) 2022-10-26 2025-09-03 Ecofibre USA Inc. Stabilized compositions comprising cannabidiol
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566560B2 (en) * 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US20040039048A1 (en) * 2000-02-11 2004-02-26 Manuel Guzman Pastor Therapy with cannabinoid compounds for the treatment of brain tumors
ES2164584A1 (es) * 2000-02-11 2002-02-16 Univ Madrid Complutense Terapia con cannabinoides para el tratamiento de tumores cerebrales.
RU2166948C1 (ru) * 2000-05-29 2001-05-20 Центральный научно-исследовательский рентгенорадиологический институт Способ лечения глиом с эпилептическим синдромом
EP1326996A4 (en) * 2000-09-14 2005-08-24 Univ California ID-1 AND ID-2 GENES AND PRODUCTS AS DIAGNOSIS AND PROGNOSIS MARKERS AND THERAPEUTIC OBJECTIVES OF THE TREATMENT OF BREAST CANCER AND OTHER CARCINOMA SPECIES
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20080057117A1 (en) * 2002-02-15 2008-03-06 Forschungs Institut Miscia Verenfur Krebsforschung Pharmaceutical composition made up of cannibus extracts
IL148244A0 (en) * 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
US7285687B2 (en) * 2002-04-25 2007-10-23 Virginia Commonwealth University Cannabinoids
US6946150B2 (en) * 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
UA71391A (uk) * 2003-12-26 2004-11-15 Інститут Нейрохірургії Імені Академіка А. П. Ромоданова Академії Медичних Наук України Спосіб променевої терапії при лікуванні гліом головного мозку
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
MX2007012157A (es) * 2005-04-01 2008-03-14 Intezyne Technologies Llc Micelas polimericas para suministro de farmacos.
US7968594B2 (en) * 2005-04-27 2011-06-28 Gw Pharma Limited Pharmaceutical compositions for the treatment of pain
WO2006124698A2 (en) * 2005-05-13 2006-11-23 Unimed Pharmaceuticals, Inc. Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
KR100675281B1 (ko) * 2005-09-05 2007-01-29 삼성전자주식회사 디커플링 캐패시터를 갖는 반도체 소자 및 그 제조방법
US9084771B2 (en) * 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma

Also Published As

Publication number Publication date
AR072002A1 (es) 2010-07-28
JP5674649B2 (ja) 2015-02-25
UA104589C2 (ru) 2014-02-25
SG191643A1 (en) 2013-07-31
MX2010013036A (es) 2011-02-18
GB2475183A (en) 2011-05-11
US20210069333A1 (en) 2021-03-11
EP2320881A1 (en) 2011-05-18
ES2653200T3 (es) 2018-02-06
GB2460672B (en) 2012-01-04
RU2543034C2 (ru) 2015-02-27
GB201101072D0 (en) 2011-03-09
JP2011522028A (ja) 2011-07-28
RU2010154672A (ru) 2012-07-20
MY156264A (en) 2016-01-29
AU2009254935B2 (en) 2015-03-19
CA2726257C (en) 2016-09-13
GB2475183B (en) 2011-11-23
CN102083426B (zh) 2015-05-13
US20110086113A1 (en) 2011-04-14
CA2726257A1 (en) 2009-12-10
EP2320881B1 (en) 2017-09-20
US20190099492A1 (en) 2019-04-04
NZ589373A (en) 2013-05-31
CO6341551A2 (es) 2011-11-21
ZA201008558B (en) 2014-11-26
GB2460672A (en) 2009-12-09
KR20110053944A (ko) 2011-05-24
AU2009254935A1 (en) 2009-12-10
ES2887084T3 (es) 2021-12-21
TW201002316A (en) 2010-01-16
IL209739A0 (en) 2011-02-28
GB0810203D0 (en) 2008-07-09
TWI469777B (zh) 2015-01-21
CN102083426A (zh) 2011-06-01
WO2009147438A1 (en) 2009-12-10
DK2320881T3 (en) 2018-01-02
BRPI0911384A2 (pt) 2015-12-29
PT2320881T (pt) 2017-12-22
JP2015057411A (ja) 2015-03-26
EP3213748A1 (en) 2017-09-06
EP3213748B1 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
BRPI0911384A8 (pt) Canabinóides em combinação com agentes quimioterápêuticos não canabinóides (por exemplo, agentes de alquilação ou serm)
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
CL2008002381A1 (es) Oligonucleotido inmunoestimulador; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno o afeccion en un sujeto, incluyendo cancer.
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
BRPI0714399B8 (pt) composição farmacêutica líquida oral
BR112014026166A2 (pt) dispositivo de tratamento de escape integrado tendo uma configuração compacta
BRPI0921249A2 (pt) uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterapico na preparação de uma composição,e composições para o tratamento do cãncer.
BR112012024480A8 (pt) Uso de fitocanabinóides canabidivarina (cbdv) no tratamento da epilepsia
CL2011002962A1 (es) Uso de al menos un ligando especifico de integrina para el tratamiento de cancer, y donde el medicamento es para ser usado en combinacion con al menos un agente adicional seleccionado de a) uno o mas agentes alquilantes y b) uno o mas agentes quimioterapeuticos diferente a los anteriores.
NI201000183A (es) Regímenes de dosificación de antiprogestina.
BR112015006087A2 (pt) microcápsulas biodegradáveis contendo material de enchimento
BR112012012610A2 (pt) terapia de combinação para o tratamento de câncer e ensaios diagnósticos para o uso na mesma
UY31079A1 (es) Derivados de fenilaminobenceno sustituidos de utilidad para el tratamiento de trastornos y enfermedades hiperproliferativos asociados con actividad quinasa extracelular mediada por mitógenos
BR112012012210A2 (pt) polímeros á base de ciclodextrina para distribuição terapêutica
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
CL2012001539A1 (es) Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo.
CL2011002595A1 (es) Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion.
AR080483A1 (es) Metodo para estabilizar dispersiones acuosas de compuestas bioactivos en agua
BR112015005779A2 (pt) toner, revelador e aparelho de formação de imagem
BR112012003806A2 (pt) aptâmero, composição farmac~eutica, m´todo para tratar, prevenir, retardar a progressão ou melhorar um distúrbio de sangramento mediado por inibidor de via de fator tecidual, kit, agente de reversão,e, métodos para produzir um aptâmero que se liga a inibidor de via de fator tecidual, e para produzir um agente de reversão.
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
PE20081881A1 (es) Agentes terapeuticos para canceres resistentes a agentes quimioterapicos que incluyen como ingrediente activo un anticuerpo que reconoce hla de clase i y sus usos
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: GW PHARMA LIMITED (GB) , OTSUKA PHARMACEUTICAL CO LIMITED (JP)

Owner name: GW PHARMA LIMITED (GB) , OTSUKA PHARMACEUTICAL CO

B25A Requested transfer of rights approved

Owner name: GW PHARMA LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: GW PHARMA LIMITED (GB)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements